EZH2 and cancer: However, recent reports have disclosed that unlike DZNep, which is thought to deplete PRC2 subunits in cancer cells by way of an indirect mechanism [35], other EZH2 inhibitors, such as GSK343, are able to directly and selectively inhibit PRC2 enzymatic activity, probably increasing their efficacy [36].